Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma

Several new drugs and regimens have greatly improved outcomes in multiple myeloma, but the rapid emergence of new targets and immune-based modalities has added significant complexity to the management of relapsed and refractory multiple myeloma (RRMM). Teclistamab is a T cell-redirecting anti-CD3 × anti-B cell maturation antigen bispecific antibody recently approved as monotherapy against RRMM. The drug is now the fourth B cell maturation antigen-targeting agent commercially used in RRMM and the third different drug class and mechanism of action doing so. Although approved as a single agent in relapsed and refractory disease, preclinical and clinical evidence has supported teclistamab-based regimens for use in earlier lines or in combination strategies. The identification of novel suitable cell-surface targets in multiple myeloma and the promising efficacy seen in early-phase studies represent additional innovations to the treatment paradigms for RRMM.